Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 7/20 | 0.43 |
| ▸ | MC4R | P32245 | 10/20 | 0.42 |
| ▸ | MC3R | P41968 | 2/20 | 0.40 |
| ▸ | MC5R | P33032 | 1/20 | 0.40 |
| ▸ | MC1R | Q01726 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12713338 | 1.00 | CALCA (0.43) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL12713332 | 0.91 | CALCA (0.43) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL12713335 | 0.91 | CALCA (0.43) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL12713219 | 0.89 | CALCA (0.44) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL12713236 | 0.88 | CALCA (0.44) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL12713202 | 0.85 | CALCA (0.48) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL13002977 | 0.85 | MC4R (0.46) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL12713330 | 0.85 | MC4R (0.46) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL12713328 | 0.85 | MC4R (0.46) | CALCAMC4RMC3RMC5RMC1R | |
| SCHEMBL12713130 | 0.84 | MC4R (0.47) | CALCAMC4RMC3RMC5RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| WO-2007115798-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | CALCA 3805/4885MC4R 1/4885MC3R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.